Transplant Diagnostics Market worth 753.9 M USD by 2021

Wednesday 11 May 2016, Amsterdam

$ The report, now available on ASDReports, "Transplant Diagnostics Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The Global Transplant Diagnostics Market Is Projected to reach USD 753.9 Million by 2021 From USD 535.0 Million in 2016, at a CAGR of 7.1%, during 2016 to 2021

On basis of technology, the transplant diagnostics market is categorized into molecular assay technology [including PCR-based (Sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assays). The molecular assay segment is expected to account for the larger share of the global transplant diagnostics market in 2016. The sequencing-based molecular assay segment is projected to grow faster than the PCR-based molecular assay segment, growing at a double-digit CAGR during 2016–2021. Growth in the sequencing-based molecular assay segment is mainly driven by the growing market demand for high-throughput DNA sequencers in HLA typing, rising end-user preference for low-cost and efficient DNA sequencing technologies, expansion in application horizons of NGS in tissue typing, and increasing usage of NGS systems among researchers and diagnostic laboratories. The PCR-based molecular assay segment is expected to hold a larger share of the global transplant diagnostics market for molecular assay technology in 2016.

Factors such as growing number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments are the key market drivers for the transplant diagnostics industry. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedure restrain the growth of the market to a certain extent. Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide opportunities for players in the transplant diagnostics market. The significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global transplant diagnostics market.

In 2016, North America and Europe are expected to be the mature markets for transplant diagnostic products. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the transplant diagnostics market in the next five years. The North American transplant diagnostics market is expected to hold the largest share of the global transplant diagnostics market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of transplant diagnostics.

As of 2015, the key players in the transplant diagnostics market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.